Sector News

Sanofi, GSK expect further price pressure, more M&A under Trump

November 16, 2016
Life sciences

Two of Europe’s biggest drugmakers warned on Tuesday there would be no let up in pressure on U.S. medicine prices after last week’s presidential election win for Republican Donald Trump, which sent pharmaceutical and biotech shares soaring.

Mergers and acquisitions (M&A) in the sector, meanwhile, could get a big boost if Trump pushes through plans for a U.S. “tax holiday” on repatriated overseas profits, executives said.

Both France’s Sanofi and Britain’s GlaxoSmithKline have recent direct experience of U.S. pricing pressure, with healthcare providers forcing big discounts for their top-selling diabetes and respiratory medicines.

In the run-up to the U.S. election, investors had focused on the threat of price controls posed by Democrat Hillary Clinton, yet Trump also advocated a new role for government agencies in negotiating down drug costs.

“I don’t think the pricing debate is over,” Sanofi Chief Executive Olivier Brandicourt told an industry conference.

Drugmakers are already having to work much harder to justify U.S. prices due to the rising power of U.S. pharmacy benefit managers (PBMs), which administer drug benefits and negotiate rebates for employers and health plans.

The buying power of these middlemen has been brought to bear particularly in areas of medicine where there are several similar treatments to choose from, such as insulin injections and inhalers for asthma and chronic lung disease.

OVERSEAS CASH

The trend toward big buyers squeezing prices is only going to accelerate as the U.S. healthcare system struggles to find the resources to pay for new medical interventions, GSK CEO Andrew Witty said.

“It doesn’t really matter too much who won the U.S. election because the direction of travel of the U.S. marketplace, owned not by one stakeholder in the White House but by multiple stakeholders in public and private decision-making environments, is already set,” he told the Financial Times meeting.

Manufacturers contend that the discounts extracted by PBMs are not always passed on to patients.

“We are making significant concessions but patients are paying more,” said Brandicourt, who believes legislation may eventually be needed to ensure patients gain from the discounts.

Another key question for investors is the potential for a further wave of deal-making in the healthcare sector, given impetus by Trump’s plan to work with Congress to allow U.S. firms to pay a lower tax rate when bringing back overseas cash.

That would add tens of billions of dollars in firepower for pharma and biotech acquisitions, with deal-hungry Pfizer alone having more than $80 billion it wants to repatriate.

“I think there is likely to be quite a lot of M&A next year,” said GSK’s head of strategy David Redfern. “The only thing unclear is how big it gets.”

By Ben Hirschler

Source: Reuters

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).